Abstract
Deficiency of Interleukin-1 receptor antagonist (DIRA) is a rare autosomal recessive autoinflammatory disorder that occurs during the neonatal period, manifesting a spectrum of symptoms including but not limited to osteomyelitis and pustulosis. This disease results from loss-of-function mutations in the IL1RN gene, encoding the IL-1 receptor antagonist (IL-1Ra). The dysfunction of IL-1Ra may arise from two mechanisms: (i) disruptions in the folding of its secondary structure, and (ii) impaired binding to its receptor, IL-1 receptor type 1. However, limited information exists detailing broad alterations in structure and binding affinity of known IL-1Ra variants. Herein, we used a validated protein prediction model to visualize 15 unique variants, and subsequently performed a structural analysis to elucidate the mutational impacts on secondary structure and binding affinity. Our analyses revealed reduced affinity at the 5 critical binding sites (W16, Q20, Y34, Q36, and Y147) along with missing secondary structures (β-sheets, α-helices) among the variants.
Highlights
Structural analyses revealed reduced binding affinity resulting from impacts in critical binding sites of IL-1Ra.
This is the first study broadly evaluating the mutational impacts on structure and binding affinity of IL-1Ra.
A validated in silico protocol was used to predict structural alterations of the IL-1Ra variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study received no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data acquisition section is now updated. Methodologies used for analyses for secondary structures and binding sites are now updated. Table 1 is now updated.
Data Availability
All supporting data and analysis is available in Supplementary Materials 1.
